Abstract: The present invention regards oligonucleotides for modulating the expression of a gene, in particular for modulating a gene responsible for a pathology of genetic, tumoral or viral origin. Moreover, the present invention relates to the use of said oligonucleotides, possibly chemically modified, for the treatment and/or the diagnosis of said diseases.

Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.

Abstract: This present invention provides methods for the detection of small molecules in samples comprising the steps a) coupling a nanoparticle (NP) or microparticle (MP) to an aptamer specific for the small molecule to be detected to form a NP-aptamer conjugate b) contacting the NP-aptamer conjugate with the sample; and c) detecting a change in the size, surface potential, or mobility of the NP-aptamer conjugate, wherein the change is indicative of the presence of the small molecule. The present invention also provides for and a biosensor comprising nanoparticles coupled to aptamers to provide nanoparticle aptamer-conjugates (NP-aptamer).

Abstract: A DNA aptamer was obtained which has an affinity for His-tag, and contains a nucleotide sequence selected from SEQ ID No. 1 and SEQ ID No. 2, which has clear applications.

Abstract: The present invention relates to polyC:poly(G/I) dsRNAs for triggering innate immunity, in particular through toll-like receptor 3 (TLR-3) and, optionally, RIG-I or RIG-I-like receptors (RLRs), as well as compositions and medicaments containing such dsRNAs, methods for their production and their use in medicine, especially immunostimulation and prevention and/or therapy of infections and tumor diseases.

Abstract: The present invention relates to mutants of a parent Trichoderma strain, comprising a polynucleotide encoding a polypeptide and one or more genes selected from the group consisting of a peptaibol synthetase gene, a paracelsin synthetase gene, a first terpene cyclase gene, a second terpene cyclase gene, and a third terpene cyclase gene, wherein one or more of the genes are modified rendering the mutant strain deficient in the production of one or more of the enzymes selected from the group consisting of a peptaibol synthetase, a paracelsin synthetase, a first terpene cyclase, a second terpene cyclase, and a third terpene cyclase compared to the parent Trichoderma strain when cultivated under identical conditions. The present invention also relates to methods of producing a polypeptide in such mutants and methods for producing such mutants.

Abstract: The present invention provides transgenic plants having increased tolerance to cold and altered flowering characteristics. Also provided are methods and compositions for producing said transgenic plants.

Abstract: Polypeptides and recombinant DNA molecules useful for conferring tolerance to AOPP herbicides, phenoxy acid herbicides, and pyridinyloxy acid herbicides are provided in the present invention, as well as herbicide tolerant transgenic plants, seeds, cells, and plant parts containing the recombinant DNA molecules, as well as methods of using the same.

Abstract: The present invention relates to a method of increasing resistance against fungal pathogens of the order Pucciniales, preferably the family Phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an HCP5 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells. Furthermore, the invention relates to transgenic plants, plant parts, and/or plant cells having an increased resistance against fungal pathogens, in particular, pathogens of the order Pucciniales, preferably the family Phacopsoraceae, and to recombinant expression vectors comprising a sequence that is identical or homologous to a sequence encoding an HCP5 protein.

Abstract: Engineered pesticidal polypeptides that are highly active against a wide range of pests and methods of making such polypeptides are disclosed. The nucleotide sequences encoding the pesticidal polypeptide can be used to transform various prokaryotic and eukaryotic organisms, which organisms can be used to produce the pesticidal polypeptides. The recombinant organisms and/or the polypeptides produced by the recombinant organisms can be used to control pests in various environments.

Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling, inhibiting growth or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity.

Abstract: The present invention relates to altering the biomass and/or structure of a plant, in order to maximize its potential as a source of feedstock or increase its potential as a feedstock for the paper industry. CLE41 and/or CLE42 are used to manipulate growth and structure of the vascular tissue of the plant. The present invention also provides plants in which the levels of CLE41 and/or CLE42 are increased compared to those of a native plant grown under identical conditions, and parts of such plants. Also provided are methods for using such plants or plant parts in the production of plant derived products such as paper or biofuels.

Abstract: The invention provides compositions and methods for reprogramming minimal volumes of mononuclear cells. In particular aspects, the invention provides methods and compositions for reprogramming minimal volumes of umbilical cord blood obtained from cord blood segments from cryopreserved cord blood segments.

Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

Abstract: The invention relates to a process of detoxifying pre-treated lignocellulose-containing material comprising subjecting the pre-treated lignocellulose-containing material to one or more phenolic compound oxidizing enzymes.

Abstract: Provided are novel hetero-oligomers of (S)-carbonyl reductases and their application in catalyzing the reduction of polyphenyl ketones. Also provided are recombinant strains expressing hetero-oligomers of SCR/SCR2 or SCR2/SCR3, which can catalyze the reduction of polyphenyl ketones. The hetero-oligomer of SCR/SCR2 is capable of catalyzing 2,4-dichlorobenzophenone, 2-naphthalenone and [(E)-2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoic acid methyl ester (Keto Easter M) with a specific activity of 4.55 U/mg, 2.43 U/mg and 0.86 U/mg, respectively. The hetero-oligomer of SCR2/SCR3 is capable of catalyzing 2,4-dichlorobenzophenone and [(E)-2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoic acid methyl ester (Keto Easter M) with a specific activity of 4.42 U/mg and 1.21 U/mg, respectively.

Abstract: Provided are a method for treating a saccharide solution, which comprises subjecting a saccharide solution containing at least one selected from the group consisting of a carbonyl compound and an unsaturated alcohol other than a saccharide to hydrogenation reaction to hydrogenate the carbonyl compound and/or the unsaturated alcohol contained in the saccharide solution, a hydrogenated saccharide solution obtained by treating with the treatment method, and a method for producing an organic compound having a process of obtaining the organic compound by acting a microorganism having an organic material producing ability on an organic raw material containing the hydrogenated saccharide solution.

Abstract: According to the present invention, a microorganism belonging to the genus Aurantiochytrium having an 18S rRNA gene consisting of the base sequence represented by any of SEQ ID NOS: 1 to 5; Aurantiochytrium sp. OH4 strain; a microorganism which is a mutant obtained from the above-mentioned microorganism as a parent strain and has a higher ability to produce DHA than the parent strain; or Aurantiochytrium sp. LTR23 strain is provided. Also, a method for producing a DHA-containing composition, DHA and DHA alkyl ester by a fermentation process using the above-mentioned microorganisms is provided.

Abstract: The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilas

Abstract: The present invention relates to a method for the enzymatic synthesis of enantiomerically enriched (R)-amines of general formula [1][c] from the corresponding ketones of the general formula [1][a] by using novel transaminases. These novel transaminases are selected from two different groups: either from a group of some 20 proteins with sequences as specified herein, or from a group of proteins having transaminase activity and isolated from a microorganism selected from the group of organisms consisting of Rahnella aquatilis, Ochrobactrum anthropi, Ochrobactrum tritici, Sinorhizobium morelense, Curtobacterium pusiffium, Paecilomyces lilacinus, Microbacterium ginsengisoli, Microbacterium trichothecenolyticum, Pseudomonas citronellolis, Yersinia kristensenii, Achromobacter spanius, Achromobacter insolitus, Mycobacterium fortuitum, Mycobacterium frederiksbergense, Mycobacterium sacrum, Mycobacterium fluoranthenivorans, Burkhoideria sp.

Abstract: The present disclosure provides a method for preparing an amino acid composition using an animal byproduct, particularly a method for obtaining an amino acid composition of high quality using an animal byproduct more effectively in short time. Because an amino acid composition can be obtained from an animal byproduct more effectively and quickly using the method of the present disclosure, utilization of livestock waste, etc. can be enhanced and application as various products can be expected.

Abstract: Provided are a Corynebacterium glutamicum mutant that is resistant to high concentrations of L-glutamine, and a method of producing L-glutamine by using the mutant.

Abstract: 5-hydroxytryptophan (5-HTP), a precursor of serotonin, is produced in a microbial host cell. A modified bacterial phenylalanine 4-hydroxylase (P4H) catalyzes the tryptophan 5-hydroxylation reaction. Optionally the host cell includes a cofactor regeneration mechanism, allowing continuous production of 5-HTP without supplementation of exogenous cofactors.

Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.

Abstract: The patent discloses herein a process for the chiral resolution of racemic cyclic and acyclic acetates to obtain (R)-alcohol. Further, it discloses the resolution of racemic cyclic and acyclic acetates to obtain enantiomerically pure (R)-(?)-alcohol as single enantiomer through fungal catalyzed deacylation in single fermentation, wherein fungal strains are F. proliferatum.

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(?2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds Fc?RIIA or Fc?RIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.

Abstract: Methods of producing recombinant therapeutic fusion proteins described herein can include culturing Chinese hamster ovary (CHO) cells under conditions suitable for expression of a recombinant therapeutic fusion protein including one or more glycans, where the CHO cells have not been genetically engineered to produce terminal alpha-galactosyl residues on glycans; treating the one or more glycans of the recombinant glycoprotein with one or more exoglycosidases; measuring glycans containing terminal galactose-alpha-1-3-galactose residues on the fusion protein by nuclear magnetic resonance (NMR); and producing a recombinant therapeutic fusion protein in the CHO cells if a target level of terminal galactose-alpha-1-3-galactose residues is measured.

Abstract: A system for automated microorganism identification and antibiotic susceptibility testing comprising a reagent cartridge, a reagent stage, a cassette, a cassette, stage, a pipettor assembly, an optical detection system, and a controller is disclosed. The system is designed to dynamically adjust motor idle torque to control heat load and employs a fast focus process for determining the true focus position of an individual microorganism. The system also may quantify the relative abundance of viable microorganisms in a sample using dynamic dilution, and facilitate growth of microorganisms in customized media for rapid, accurate antimicrobial susceptibility testing.

Abstract: A system for checking interior air contamination, the system including a sealed device including twin ports, a sampling device including a pump to extract at least some of the air from the interior of the sealed device, and a microbial detect to determine if the air contains contaminants. The twin ports are removably engageable with the sampling device to allow a circuit of air between the pump unit and the sealed device, such that air extracted from one of the twin ports by the pump is returned to the other of the twin ports, allowing no escape of the air to the environment. The sealed device is sealed to prevent, except through the twin ports, exterior air to flow into the sealed device and the air from the interior to flow out.

Abstract: A biosensor chip is placed in a biosensor device and is rotated while a biochemical analysis specimen is measured, the biosensor chip comprising a main body, a holding chamber, a dispensing chamber, a plurality of quantification chambers, and a plurality of measurement chambers. The main body has an inlet into which the specimen is poured. The holding chamber holds the poured specimen inside the main body. The dispensing chamber is connected to the holding chamber via a first channel and dispenses the specimen. The quantification chambers are connected to the dispensing chamber, hold a specific amount of the dispensed specimen, and are disposed at positions located away from a rotational center of a rotary motion according to a distance from the first channel. The measurement chambers are connected to the quantification chambers via a second channel and react the specimen with a biochemical analysis reagent.

Abstract: A method of detecting Listeria monocytogenes. The method comprises providing a culture device with a selective culture medium and a detection article comprising a first indicator system. The selective culture medium facilitates the growth of Listeria microorganisms. When a Listeria microorganism is detected in a sample contacted with the culture medium, the detection article is contacted with the culture medium to detect Listeria monocytogenes.

Abstract: The present invention relates to the pharmaceutics, biotechnological and chemical, and particularly to a process for preparing a composition for detecting and measuring the concentration of endotoxins or lipopolysaccharides, peptidoglycans and (1,3)-?-D-glucans, using an extract from the hemocytes of the lobster as a starting material, the changes to the composition to increase the sensitivity, and processes for measuring endotoxins, peptidoglycans and (1,3)-?-D-glucans using said composition.

Abstract: The invention relates to method for quantification of the absolute amount of allergen in an allergen sample comprising: a) providing a known amount of one or more allergen calibration standard peptide(s) having a sequence of amino acids which is identical with, and optionally unique for, a sequence to be found in the allergen to be quantified and optionally labelling said allergen calibration standard peptide(s), b) degrading the allergen sample to obtain a mixture of peptides, and optionally labelling said peptides with one or more labelling agent(s), wherein at least the peptides in the degraded allergen sample or the calibration standard peptides are labelled, and if both the peptides in the degraded allergen sample and the allergen calibration standard peptide(s) are labelled, the labelling agent(s) used for labelling the allergen calibration standard peptide(s) are different from the labelling agent(s) used for labelling the peptides of the degraded allergen sample, c) quantifying the absolute amount

Abstract: The present invention provides, among other things, methods for the characterization of recombinant Heparan N-Sulfatase (HNS) during manufacture. The present invention uses capillary zone electrophoresis to determine the charge profile, isoform distribution, and/or glycan profile of recombinant HNS; and represents a quality feature for the batch consistency, storage stability, biological half-life, pharmacokinetic, pharmacodynamic and biological activity of the enzyme. In particular, such characterization methods may be beneficial to optimize conditions and ensure consistency for the manufacture of HNS for the treatment of a patient diagnosed with Sanfilippo syndrome using enzyme replacement therapy.

Abstract: Disclosed are methods of detecting enzymatic activity on a fluorophore-labeled substrate using by monitoring the fluorescence lifetime of the fluorophore.

Abstract: Provided herein is an all-in-one saliva collection apparatus that collects saliva to allow for the filtration of saliva in order to separate saliva components, such as extracellular proteins and nucleic acids that are not present in intact cells, from the intact cells and debris remaining in the extracted sample. The filtered saliva samples can be aliquoted into two fractions for protein and/or nucleic acid analysis. The present invention further describes long term storage at ambient temperatures of filtered salivary nucleic acids, and long term storage at ambient temperatures of filtered salivary proteins added to an ethanol solution. The filtered cell-free saliva samples have diagnostic usefulness.

Abstract: The present invention is based on a detection method of the 9 KRAS mutations Gly12Ser, Gly12Arg, Gly12Cys, Gly12Asp, Gly12Ala, Gly12Val, Gly13Asp, Gln61His and Gln61Leu, in a sample susceptible of containing one or more of such mutations, based on amplification of the sample with the primers of the present invention. Further, the present invention relates to (i) a kit which comprises, amongst its components, reagents for ARMS amplification including one or more of the primers of the present invention; (ii) the primers themselves; and (iii) use of the method, kit and primers of above, for the diagnosis/prognosis of a pathological condition in a patient, particularly, of cancer.

Abstract: The present invention relates to a novel method for detecting a target polynucleotide having a target sequence, comprising (a) exposing the target polynucleotide to an initiating oligonucleotide; (b) extending the initiating oligonucleotide with an extended sequence complementary to the target sequence; (c) ligating the initiating oligonucleotide sequence with the extended sequence to form a circular oligonucleotide having a nicking endonuclease (NE) recognition/cutting sequence; (d) exposing the circular oligonucleotide to a DNA polymerase and a DNA synthesis primer to synthesize DNA having a NE recognition sequence; (e) exposing the synthesized DNA to a probe having the NE recognition/cutting sequence to form a double stranded DNA having a full NE site; (f) exposing the double stranded DNA to a nicking endonuclease (NE) to cleave the probe; and (g) detecting the cleaved probe. The presence of the cleaved probe indicates the presence of the target polynucleotide.

Abstract: Provided in the present invention are a method for constructing a nucleic acid single-stranded cyclic library and reagent kit thereof. The method comprises the steps of using a transposase embedding complex to randomly break nucleic acids and connect a first linker; connecting a second linker at a gap; performing a first PCR reaction, wherein the 5? end of one of the primers has a first affinity tag, resulting in a product with two ends connected to different linker sequences; binding the product to a solid vector having a second affinity tag; degenerating and separating single strands having no affinity tag; and cyclizing the single strands.

Abstract: The present invention relates to a high throughput method for the identification and detection of molecular markers wherein restriction fragments are generated and suitable adaptors comprising (sample-specific) identifiers are ligated. The adapter-ligated restriction fragments may be selectively amplified with adaptor compatible primers carrying selective nucleotides at their 3? end. The amplified adapter-ligated restriction fragments are, at least partly, sequenced using high throughput sequencing methods and the sequence parts of the restriction fragments together with the sample-specific identifiers serve as molecular marker.

Abstract: A method is described for detecting a target nucleic acid, in which the target nucleic acid is amplified in the presence of a proofreading DNA polymerase and an allele-specific reactive primer (ASRP) including (i) a nucleotide sequence complementary to the target nucleic acid and (ii) modified nucleotide(s) located in a region from a nucleotide located right before a non-complementary nucleotide on the 5?-side of the non-complementary nucleotide, so that an amplification product of the target nucleic acid is produced when the ASRP is complementary to the target nucleic acid, and so that when the ASRP is not complementary to the target nucleic acid, an amplification product of the target nucleic acid will not be produced. The detection method has a very high specificity of amplification, and is useful for applications such as detecting mutations, detecting methylation of CpG after bisulfite treatment, and detecting target DNA from a DNA library.

Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosine (5hmC) and/or 5-methylcytosine (5meC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC and/or 5meC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.

Abstract: This disclosure provides methods and compositions for tagging long fragments of a target nucleic acid for sequencing and analyzing the resulting sequence information in order to reduce errors and perform haplotype phasing, for example.

Abstract: Computer implemented methods, and systems performing such methods for processing signal data from analytical operations and systems, and particularly in processing signal data from sequence-by-incorporation processes to identify nucleotide sequences of template nucleic acids and larger nucleic acid molecules, e.g., genomes or fragments thereof.

Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.

Abstract: The present invention relates to the field of single nucleotide polymorphisms (SNPs) and uses therefore as a predictor of diseases and conditions. Specifically, the present invention provides methods and kits useful in determining whether a subject is at increased risk for developing a cardiovascular disease by screening for the presence of a SNP in the scavenger receptor class B type I (SR-BI) gene of a subject.

Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.

Abstract: The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated.

Abstract: Compositions and methods for determining circulating biomolecules before, during, and/or after treatment of a patient with an anti-cancer or anti-tumor drug (or putative drug) are described. Methods of treatments based on the compositions and methods described herein are also provided. Noninvasive methods and kits are provided for assessing the efficacy of an anti-cancer therapy for killing or damaging cancer cells. Embodiments are used to determine the cancer-killing efficacy of an anti-cancer drug in a patient, to optimize the selection of an anti-cancer drug for treatment of a patient, to adjust the dosage of an anti-cancer drug for treatment of a particular cancer in a patient and for identifying useful anti-cancer therapeutics for any one particular type of cancer.